Skye Bioscience Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Skye Bioscience does not have a record of paying a dividend.

Wichtige Informationen

n/a

Dividendenausschüttung

-56.6%

Rückkaufsrendite

Gesamte Aktionärsrendite	-56.6%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if SKYE's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if SKYE's dividend payments have been increasing.

Dividendenrendite im Vergleich zum Markt

Skye Bioscience Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von SKYE im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (SKYE)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.5%
Branchendurchschnitt (Biotechs)	2.2%
Analystenprognose (SKYE) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Unable to evaluate SKYE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate SKYE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate SKYE's payout ratio to determine if its dividend payments are covered by earnings.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as SKYE has not reported any payouts.

Skye Bioscience Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen